Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 3/20 | 0.33 |
| ▸ | CCND1 | P24385 | 3/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL476706 | 0.85 | MCL1 (0.36) | CDK4CCND1MCL1HDAC6HDAC1 | |
| SCHEMBL476691 | 0.80 | MCL1 (0.33) | CDK4CCND1MCL1HTR2AHTR2C | |
| SCHEMBL476708 | 0.74 | HTT (0.46) | MCL1HDAC6HDAC1HDAC8HTR2A | |
| SCHEMBL476728 | 0.70 | SIGMAR1 (0.35) | SIGMAR1HTR2AHTR2C | |
| SCHEMBL16244758 | 0.65 | CDK4 (0.78) | SIGMAR1CDK4CCND1HTR2AHTR2C | |
| SCHEMBL2184235 | 0.63 | ADRA2A (0.45) | CDK4CCND1 | |
| SCHEMBL4827327 | 0.63 | DBH (0.33) | — | |
| SCHEMBL14066612 | 0.63 | ADRA2A (0.32) | — | |
| SCHEMBL18911783 | 0.60 | CDK4 (0.81) | CDK4CCND1HTR2AHTR2C | |
| SCHEMBL5841534 | 0.58 | ACLY (0.49) | CDK4CCND1MCL1HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951225-B1 | 3-ACYLINDOLE DERIVATIVES THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2012-02-01 | — | — | EP | disclosed |
| US-7741363-B2 | 3-Acylindole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-06-22 | — | — | US | disclosed |
| US-20080275102-A1 | 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275102-A1 | 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | F12, ECI1, NQO2 | SIGMAR1 285/4885CDK4 1606/4885CCND1 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.